Podcast Episodes
Back to SearchSequencing BTK inhibitor therapy in CLL: treatment considerations and emerging strategies
Episode 345
This podcast explores sequencing strategies and treatment considerations for BTK inhibitors in chronic lymphocytic leukemia (CLL). Jennifer Brown, MD…
3 months ago
Precision medicine in AML: from targeted therapy to transplantation
Episode 344
This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted…
3 months, 1 week ago
MPNs in focus: disease progression, risk assessment, and emerging treatments
Episode 343
This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myel…
3 months, 2 weeks ago
The evolving role of cellular therapies and T-cell engagers in lymphoma
Episode 342
This VJHemOnc podcast explores emerging cellular therapies and T-cell engagers in non-Hodgkin lymphoma (NHL). Krish Patel, MD, Sarah Cannon Research …
4 months ago
Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure
Episode 341
This VJHemOnc podcast explores how evolving treatment strategies, immunotherapies, and MRD-driven approaches are reshaping the management of multiple…
4 months, 1 week ago
Dual-targeting CAR T-cell therapies in LBCL: efficacy, safety, and bridging therapy
Episode 340
This VJHemOnc podcast features a roundtable discussion from the 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) 2026 on the evolving ro…
4 months, 2 weeks ago
Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation
Episode 339
This VJHemOnc podcast explores the latest advances in gene-based therapies for sickle cell disease (SCD) and thalassemia, highlighting progress in p…
4 months, 3 weeks ago
Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians
Episode 337
In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, L…
5 months, 1 week ago
The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care
Episode 336
This VJHemOnc episode explores major shifts in frontline mantle cell lymphoma (MCL) care, highlighting the move from traditional chemotherapy to chem…
5 months, 2 weeks ago